(R)-N-(2-Chloro-6-methylphenyl)-2-(3-methyl-1-piperazinyl)imidazo[1,5-a]pyrido[3,2-e]pyrazin-6-amine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: (R)-N-(2-Chloro-6-methylphenyl)-2-(3-methyl-1-piperazinyl)imidazo[1,5-a]pyrido[3,2-e]pyrazin-6-amine
• 英文别名: N-(2-chloro-6-methylphenyl)-12-[(3R)-3-methylpiperazin-1-yl]-2,4,8,13-tetrazatricyclo[7.4.0.02,6]trideca-1(9),3,5,7,10,12-hexaen-7-amine
• 化学式: C₂₁H₂₂ClN₇
• 分子量: 407.906
• InChiKey: PUNYTBZWCMNSRO-CQSZACIVSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.6
• 重原子数：
  29
• 可旋转键数：
  3
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  70.4
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  2,6-二氯-3-氨基吡啶 在 sodium hexamethyldisilazane 、 potassium carbonate 、 三氯氧磷 作用下， 以 四氢呋喃 、 N,N-二甲基乙酰胺 为溶剂， 反应 6.0h， 生成 (R)-N-(2-Chloro-6-methylphenyl)-2-(3-methyl-1-piperazinyl)imidazo[1,5-a]pyrido[3,2-e]pyrazin-6-amine
  参考文献：
  名称：

  Imidazoquinoxaline Src-Family Kinase p56^Lck Inhibitors:  SAR, QSAR, and the Discovery of (S)-N-(2-Chloro-6-methylphenyl)-2-(3-methyl-1-piperazinyl)imidazo- [1,5-a]pyrido[3,2-e]pyrazin-6-amine (BMS-279700) as a Potent and Orally Active Inhibitor with Excellent in Vivo Antiinflammatory Activity

  摘要：

  A series of novel anilino 5-azaimidazoquinoxaline analogues possessing potent in vitro activity against p56(Lck) and T cell proliferation have been discovered. Subsequent SAR studies led to the identification of compound 4 (BMS-279700) as an orally active lead candidate that blocks the production of proinflammatory cytokines (IL-2 and TNFalpha) in vivo. In addition, an expanded set of imidazoquinoxalines provided several descriptive QSAR models highlighting the influence of significant steric and electronic features. The H-bonding (Met319) contribution to observed binding affinities within a tightly congeneric series was found to be significant.

  DOI：

  10.1021/jm030217e

文献信息

• [EN] HETEROCYCLO-SUBSTITUTED IMIDAZOPYRAZINE PROTEIN TYROSINE KINASE INHIBITORS<br/>[FR] INHIBITEURS DE LA PROTEINE TYROSINE KINASE, A BASE D'IMIDAZOPYRAZINE A SUBSTITUTION HETEROCYCLO
  申请人：BRISTOL-MYERS SQUIBB COMPANY

  公开号：WO1999045009A1

  公开（公告）日：1999-09-10

  (EN) Novel heterocyclo-substituted imidazopyrazines and salts thereof, pharmaceutical compositions containing such compounds, and methods of using such compounds in the treatment of protein tyrosine kinase-associated disorders such as immunologic disorders.(FR) L'invention concerne des imidazopyrazines à substitution hétérocyclo, et des sels de celles-ci, des compositions pharmaceutiques contenant de tels composés, ainsi que des procédés d'utilisation de ces composés dans le traitement de troubles associés à la protéine tyrosine kinase, tels que des troubles d'ordre immunologique.

  （中）本发明涉及一种新型的杂环取代咪唑吡嗪及其盐，含有此类化合物的药物组合物，以及在治疗蛋白酪氨酸激酶相关疾病，如免疫系统疾病中使用此类化合物的方法。
• HETEROCYCLO-SUBSTITUTED IMIDAZOPYRAZINE PROTEIN TYROSINE KINASE INHIBITORS
  申请人：Bristol-Myers Squibb Company

  公开号：EP1066286B1

  公开（公告）日：2009-04-29
• EP1066286A4
  申请人：——

  公开号：EP1066286A4

  公开（公告）日：2004-02-11
• US5990109A
  申请人：——

  公开号：US5990109A

  公开（公告）日：1999-11-23
• Imidazoquinoxaline Src-Family Kinase p56^Lck Inhibitors:  SAR, QSAR, and the Discovery of (<i>S</i>)-<i>N</i>-(2-Chloro-6-methylphenyl)-2-(3-methyl-1-piperazinyl)imidazo- [1,5-<i>a</i>]pyrido[3,2-<i>e</i>]pyrazin-6-amine (BMS-279700) as a Potent and Orally Active Inhibitor with Excellent in Vivo Antiinflammatory Activity
  作者：Ping Chen、Arthur M. Doweyko、Derek Norris、Henry H. Gu、Steven H. Spergel、Jagabundhu Das、Robert V. Moquin、James Lin、John Wityak、Edwin J. Iwanowicz、Kim W. McIntyre、David J. Shuster、Kamelia Behnia、Saeho Chong、Henry de Fex、Suhong Pang、Sydney Pitt、Ding Ren Shen、Sara Thrall、Paul Stanley、Octavian R. Kocy、Mark R. Witmer、Steven B. Kanner、Gary L. Schieven、Joel C. Barrish

  DOI：10.1021/jm030217e

  日期：2004.8.1

  A series of novel anilino 5-azaimidazoquinoxaline analogues possessing potent in vitro activity against p56(Lck) and T cell proliferation have been discovered. Subsequent SAR studies led to the identification of compound 4 (BMS-279700) as an orally active lead candidate that blocks the production of proinflammatory cytokines (IL-2 and TNFalpha) in vivo. In addition, an expanded set of imidazoquinoxalines provided several descriptive QSAR models highlighting the influence of significant steric and electronic features. The H-bonding (Met319) contribution to observed binding affinities within a tightly congeneric series was found to be significant.